Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Lowered to $166.00 at Piper Sandler

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target dropped by stock analysts at Piper Sandler from $188.00 to $166.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s price target would suggest a potential upside of 44.16% from the stock’s current price.

Several other brokerages also recently issued reports on JAZZ. UBS Group lowered their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a report on Tuesday, July 2nd. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. Morgan Stanley lowered their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. Barclays lowered their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Finally, Wells Fargo & Company decreased their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.87.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $4.90 during trading on Thursday, hitting $115.15. The company had a trading volume of 957,486 shares, compared to its average volume of 677,389. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The firm has a market capitalization of $7.26 billion, a P/E ratio of 23.74, a price-to-earnings-growth ratio of 1.73 and a beta of 0.58. The stock’s 50-day moving average price is $107.47 and its 200 day moving average price is $114.15. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Equities analysts expect that Jazz Pharmaceuticals will post 15.31 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the stock. Kovack Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 88.8% during the 1st quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after purchasing an additional 26,628 shares during the last quarter. Baupost Group LLC MA boosted its holdings in Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after purchasing an additional 160,000 shares during the period. Polaris Capital Management LLC boosted its holdings in Jazz Pharmaceuticals by 2.2% in the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after purchasing an additional 27,100 shares during the period. John G Ullman & Associates Inc. bought a new position in Jazz Pharmaceuticals in the 1st quarter valued at $3,631,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at $380,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.